Incyte Pipeline

April 27, 2015

INCYTE Pipeline

JAK = Janus-associated kinase; IDO1 = indoleamine 2,3-dioxygenase; PI3K= phosphatidylinositol 3-kinase; FGFR = fibroblast growth factor receptor; BRD = Bromodomain

a. Incyte licensed rights outside the United States to Novartis and retained US rights.
b. Jakafi is approved for treatment of people with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF.
c. Jakafi is approved for treatment of people with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea.
d. In combination with Merck’s pembrolizumab.
e. In combination with Genentech’s MPDL3280A.
f. In combination with AstraZeneca/MedImmune’s MEDI4736.
g. In combination with Bristol-Myers Squibb’s nivolumab.
h. Incyte licensed worldwide rights to Novartis and retained codevelopment and copromotion options.
i. Incyte licensed worldwide rights to Eli Lilly and Company and elected to codevelop with Lilly and retained a copromotion option.
j. Incyte licensed worldwide rights to Lilly and retained a copromotion option.
k. Incyte licensed worldwide rights to Lilly and retained codevelopment and copromotion options.